Skip to main content
QSI logo

QSI · Quantum-Si Inc · Documents

Track QSI — free
$0.91 -0.16 (-15.05%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$199.75M
Shares
219.74M
Volume · Nov 20 7.82M Avg daily vol (3M) 6.87M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $2.44M down 20.3% 10-K filed Mar 3, 2026 Quarterly report FY2026 Q3 Revenue $212K down 61.6% 10-Q filed Nov 5, 2026 Latest results Proteus on track for Q2 2027 launch despite lower revenue 8-K filed Nov 5, 2026 Earnings call Q3 2026 earnings call Held Nov 5, 2026
2026
Nov 18
Current report 8-K
Proteus Detects All 20 Amino Acids, Ahead of Year-End Goal

Quantum-Si has demonstrated detection of all 20 naturally occurring amino acids in its Proteus development program, achieving its year-end 2026 goal ahead of schedule. It is working to incorporate that detection into a developmental sequencing kit for Proteus instruments.

Regulation FD disclosure
2 source passages
it has demonstrated detection of all 20 naturally occurring amino acids in its Proteus development program, achieving its year-end 2026 goal ahead of schedule Quantum-Si is now working to incorporate 20 amino acid detection into a developmental sequencing kit for use on Proteus instruments Open the document at this passage
Nov 5
Earnings call
Proteus launch remains on track for second quarter 2027

Quantum SI says Proteus remains on track for a second quarter 2027 launch, expects detection of the 20th amino acid before the end of the year, and has sufficient capital through the fourth quarter of 2028.

4 source passages
Proteus remains on track for launch in the second quarter of 2027. Based on the progress we have made and the pace of advancement we are seeing, we believe we are well positioned to demonstrate detection of the 20th amino acid before the end of the year. We continue to believe we have sufficient capital to execute the key activities required for the Proteus launch and fund operations into the fourth quarter of 2028. We firmly believe that current revenue does not capture Quantum SI's long-term value potential. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue falls 59.0%; restructuring cuts 20% of workforce

Quantum-Si reported nine-month revenue down 59.0% and net loss of $67.5 million, while an August 2026 restructuring terminated approximately 20% of its 152 employees. Proteus is estimated to launch in the second quarter of 2027.

Revenue $212K ▼ 61.6% Net loss $22.32M Diluted EPS -$0.10
Read from the MD&A section
4 source passages
Total revenue for the sale of our Platinum line of instruments, related reagent kits and service maintenance contracts decreased by $0.3 million, or 61.6%, and $1.2 million, or 59.0%, for the three and nine months ended September 30, 2026, respectively, when compared to the same periods in 2025. Net cash used in operating activities was $64.6 million during the nine months ended September 30, 2026. Net cash used was primarily attributable to our net loss of $67.5 million, resulting from continued spend on research and development and commercialization efforts. As a result, we terminated approximately 20% of our 152 employee workforce. ProteusTM, our next-generation platform, which was announced in November 2024 and is estimated to be launched in the second quarter of 2027. Open the document at this passage
Nov 5
Current report 8-K
Proteus on track for Q2 2027 launch despite lower revenue

Quantum-Si reported third-quarter revenue of $212,000, down from $552,000, as the Platinum-to-Proteus transition continued. Proteus remains on track for a Q2 2027 launch, while 2026 revenue guidance stayed at approximately $1.0 million and cash runway was reaffirmed into Q4 2028.

Financial results
5 source passages
Quantum-Si Reports Third Quarter 2026 Financial Results and Provides Business Update Proteus™ remains on track for anticipated Q2 2027 commercial launch For the third quarter of 2026, the Company recorded revenue of $212,000, compared to $552,000 in the third quarter of 2025. Revenue: Approximately $1.0 million The Company believes its cash, cash equivalents and investments in marketable securities of $149.4 million as of September 30, 2026, together with its cost-reduction actions, will support the Company’s operating plan into the fourth quarter of 2028. Open the document at this passage
Oct 15
Current report 8-K Events of Oct 14
Regains Nasdaq Minimum Bid Price Compliance as of October 13

Quantum-Si regained compliance with Nasdaq's minimum bid price requirement as of October 13, 2026, closing the matter. The company will keep monitoring its bid price, and a future shortfall could again trigger delisting notice.

Other events
3 source passages
On October 14, 2026, the Staff notified the Company that, as of October 13, 2026, the Company had regained compliance with the Bid Price Requirement and that the matter is now closed. The Company will continue to monitor the closing bid price of its Common Stock in the future. If the Company does not maintain compliance with Nasdaq Listing Rule 5450(a)(1) in the future, it is likely that Nasdaq will once again provide notice that the Company’s Class A common stock will be subject to delisting. Open the document at this passage
Oct 8
Current report 8-K
Regulation FD disclosure

Quantum-Si demonstrated detection of 19 amino acids in its Proteus development program and is working to deploy the capability into a developmental sequencing kit; it remains confident in demonstrating detection of all 20 amino acids by year-end 2026.

Sep 29
Current report 8-K Events of Sep 28
Regulation FD disclosure

Quantum-Si said interim Proteus data showed 30 times more single-chamber alignments than Platinum Pro, a 4.8-fold lower median false discovery rate, and detection of all 24 proteins in a 24-protein panel; Proteus remains on track for Q2 2027.

Aug 13
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $344K ▼ 41.8% Net loss $23.53M Diluted EPS -$0.11
May 7
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $258K ▼ 69.4% Net loss $21.67M Diluted EPS -$0.10
Mar 3
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $2.44M ▼ 20.3% Net loss $101.34M Diluted EPS -$0.51
2025
Mar 3
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $3.06M ▲ 182.6% Net loss $101.01M Diluted EPS -$0.71
Showing 1–50 of 182 documents
Key facts CIK 1816431 CUSIP 74765K105 13F (30d) 123 filings 103 filers Visit website Investor relations